Differentiation of aborted myocardial infarction from masquerading myocardial infarction

We read with great interest the article by Verheugt et al.¹dealing with aborted myocardial infarction (MI) as a new targetfor reperfusion     

Postpartum myocardial infarction

A 29 year old woman had a myocardial infarction three weeks post partum. Coronary angiography was performed six days later. No abnormalities were seen initially, but re-injection of the left coronary artery resulted in a dissection that extended through the anterior descending and circumflex branches and a reinfarction. This case suggests that myocardial infarctions occurring in patients with angiographically normal coronary arteries may be caused by dissections that heal by the time of catheterisation.     

Acute myocardial infarction

Transient left ventricular apical ballooning or Takotsubo syndrome (TS) is characterized by transient left ventricular dysfunction, electrocardiographic changes that mimic acute myocardial infarction (AMI), and minimal release of myocardial enzymes, with no evidence of obstructive coronary artery disease. Although prognosis and outcome are relatively good, reported complications include intraventricular thrombi and embolic events. We report an extremely rare case of AMI complicating the early in‐hospital course of a patient with TS. © 2013 Wiley Periodicals, Inc.     

Non-Q-wave myocardial infarction

The rationale for introducing the term "non-Q-wave myocardial infarction" is identified. The incidence, pathology, pathogenesis, and diagnostic criteria for this condition, previously identified as nontransmural or subendocardial infarction, are reviewed. In reviewing the diagnostic criteria, the various noninvasive techniques that may be applied are discussed. The clinical course, prognosis, and management are discussed under the headings of early postinfarction period, late clinical course, predischarge evaluation, and long-term care. The issues of the management of infarct extension and acute interventional therapy are raised and reviewed. Suggestions regarding specific aspects of therapy in non-Q-wave myocardial infarction are included in the summary.     

Non-Q-Wave myocardial infarction

Opinion Statement The treatment of non-Q-wave infarction involves the use of antithrombotic therapy (aspirin and heparin) along with appropriate antianginal medication to reduce myocardial oxygen demands and prevent coronary spasm. In certain high-risk patient subgroups (ie, those with recurrent ischemia, persistent or significant ST segment change, congestive heart failure, or hypotension with chest pain), the use of newer agents such as the platelet glycoprotein IIb/IIIa antagonists is indicated. The role of angiography appears to be changing. In the past, at least in the United States, angiography was performed on nearly all patients with non-Q-wave infarction. Now, risk stratification into high- and low-risk subgroups can be performed based on clinical criteria. In low-risk individuals, we recommend that noninvasive testing be performed before a decision is made about an invasive evaluation. In high-risk patients, it is appropriate to perform angiography and, based on the angiographic findings, to provide appropriate therapy. Although the results of the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) study suggest that if bypass surgery is required, it should not be performed acutely, we do not believe that this is necessarily correct. Therapy must be individualized based on the risk-benefit profile of acute revascularization. Furthermore, the use of percutaneous coronary intervention, particularly with the glycoprotein IIb/IIIa antagonists and stents, is expanding to include multivessel disease, even in the presence of left ventricular dysfunction. Again, we believe therapy must be individualized to include an estimate of short- and long-term risk versus benefit. In the future, however, more data from appropriately designed clinical trials will be required to establish evidence-based therapy.     

Pregnancy-associated myocardial infarction

Acute myocardial infarction (AMI) is a rare, but possibly catastrophic event during pregnancy, delivery, or puerperium, leading to a high mortality rate. It has different pathogenic mechanisms, such as atherosclerosis, vasospasm, thrombosis, and coronary dissection. Although MI has been reported in pregnant women at all stages of pregnancy and postpartum, it occurs more commonly in the third trimester. Pregnancy-associated MI most commonly involves the anterior wall. Pregnancy itself is an independent risk factor for MI, conferring a fourfold higher risk than that of nonpregnant women matched for age. We report the case of a 27-year-old primigravida at 30 weeks’ gestation presenting with anterior MI, secondary to severe stenosis of the left anterior descending coronary artery, treated with emergency percutaneous coronary intervention.     

Acute myocardial infarction

Acute myocardial infarction is a common disease with serious consequences in mortality, morbidity, and cost to the society. Coronary atherosclerosis plays a pivotal part as the underlying substrate in many patients. In addition, a new definition of myocardial infarction has recently been introduced that has major implications from the epidemiological, societal, and patient points of view. The advent of coronary-care units and the results of randomised clinical trials on reperfusion therapy, lytic or percutaneous coronary intervention, and chronic medical treatment with various pharmacological agents have substantially changed the therapeutic approach, decreased in-hospital mortality, and improved the long-term outlook in survivors of the acute phase. New treatments will continue to emerge, but the greatest challenge will be to effectively implement preventive actions in all high-risk individuals and to expand delivery of acute treatment in a timely fashion for all eligible patients.     

Sportman's myocardial infarction

Sport related myocardial infarctions are rare. They concern a population mainly male, of more than 35 years, with a high prevalence of smoker. The initial clinical presentation is serious, with frequent ventricular fibrillations, the mode of revelation that can be a sudden death. The angiographic data mainly shows a single vessel disease or no significant lesion. These characteristics put down the problem of the validity of preparticipation screening for cardiovascular abnormalities, and in particular the place of exercise stress testing. It is advisable to continue the reflexion to determine a reasonable strategy in the tracking of the subjects at risk. This tracking, the correction of cardiovascular risk factors, the diffusion of elementary rules good sporting practices and the management of sudden death with rapid defibrillation on the sporting sites and complexes are current measurements essential to develop.     

Acute myocardial infarction

Modern management of acute myocardial infarction is built on a clinical evidence base drawn from many studies undertaken over the past three decades. The evolution in clinical practice has substantially reduced mortality and morbidity associated with the condition. Key to this success is the effective integration of antithrombotic therapy combined with timely reperfusion, either primary percutaneous coronary intervention or fibrinolysis for ST-elevation myocardial infarction, and invasive investigation and revascularisation for non-ST-elevation myocardial infarction, underpinned by risk stratification and optimised systems of care. After the development of troponin assays for the detection of myonecrosis, the universal definition and classification of myocardial infarction now indicates the underlying pathophysiology. Additionally, an increasing appreciation of the importance of adverse events, such as bleeding, has emerged. Remaining challenges include the effective translation of this evidence to all patients with myocardial infarction, especially to those not well represented in clinical trials who remain at increased risk of adverse events, such as elderly patients and those with renal failure. On a global level, the epidemic of diabetes and obesity in the developed world and the transition from infectious diseases to cardiovascular disease in the developing world will place an increasing demand on health-care infrastructures required to deliver time-dependent and resource-intensive care. This Seminar discusses the underlying pathophysiology, evolving perspectives on diagnosis, risk stratification, and the invasive and pharmacological management of myocardial infarction.     

Anaerobic myocardial abscess following myocardial infarction

An anaerobic myocardial abscess due to Bacteroides fragilis developed in a 60-year-old man when he had an acute myocardial infarction while recuperating from surgery for a paracolonic abscess. Anaerobic bacteremia is a common event and may lead to infection in areas of low oxygen tension far removed from the original portal of entry.